{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:08:44Z","timestamp":1794838124346,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The association between choline uptake and androgen receptor (\n                    <jats:italic>AR<\/jats:italic>\n                    ) expression is suggested by the upregulation of choline kinase-alpha in prostate cancer. Recently, detection of\n                    <jats:italic>AR<\/jats:italic>\n                    aberration in cell-free DNA as well as early 18F-fluorocholine positron emission tomography\/computed tomography (FCH-PET\/CT) were associated with outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone and enzalutamide. We aimed to make a direct comparison between circulating\n                    <jats:italic>AR<\/jats:italic>\n                    copy number (CN) and choline uptake at FCH-PET\/CT. We analysed 80 mCRPC patients progressing after docetaxel treated with abiraterone (n\u2009=\u200947) or enzalutamide (n\u2009=\u200933). We analysed\n                    <jats:italic>AR<\/jats:italic>\n                    CN from plasma samples using digital PCR and Taqman CN assays and total lesion activity (TLA) and metabolic tumor volume (MTV) on FCH-PET\/CT at baseline. A meaningful correlation was showed among\n                    <jats:italic>AR<\/jats:italic>\n                    gain and TLA\/MTV compared to\n                    <jats:italic>AR<\/jats:italic>\n                    non-gained cases (P\u2009=\u20090.001 and P\u2009=\u20090.004, respectively), independently from type of treatment. Multivariate analysis revealed that\n                    <jats:italic>AR<\/jats:italic>\n                    CN and only TLA were associated with both shorter PFS (P\u2009&lt;\u20090.0009 and P\u2009=\u20090.026, respectively) and OS (P\u2009&lt;\u20090.031 and P\u2009=\u20090.039, respectively). AR gain appeared significantly correlated with choline uptake represented mainly by TLA. Further prospective studies are warranted to better address this pathway of AR-signalling and to identify multiplex biomarker strategies including plasma\n                    <jats:italic>AR<\/jats:italic>\n                    and FCH-PET\/CT in mCRPC patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-15928-y","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T07:18:05Z","timestamp":1510125485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Circulating androgen receptor combined with 18F-fluorocholine PET\/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer"],"prefix":"10.1038","volume":"7","author":[{"given":"V.","family":"Conteduca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Scarpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Caroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L.","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Schepisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Testoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gurioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Casadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Matteucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"key":"15928_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA Cancer J Clin. \n                           67, 7\u201330 (2017).","journal-title":"CA Cancer J Clin."},{"key":"15928_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard, G. et al. Prostate cancer. Lancet \n                           387, 70\u201382 (2016).","journal-title":"Lancet"},{"key":"15928_CR3","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","volume":"28","author":"V Conteduca","year":"2017","unstructured":"Conteduca, V. et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol. \n                           28, 1508\u20131516 (2017).","journal-title":"Ann Oncol."},{"key":"15928_CR4","doi-asserted-by":"publisher","first-page":"37839","DOI":"10.18632\/oncotarget.9341","volume":"7","author":"S Salvi","year":"2016","unstructured":"Salvi, S. et al. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. Oncotarget \n                           7, 37839\u201337845 (2016).","journal-title":"Oncotarget"},{"key":"15928_CR5","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/bjc.2015.128","volume":"112","author":"S Salvi","year":"2015","unstructured":"Salvi, S. et al. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br J Cancer \n                           112, 1717\u20131724 (2015).","journal-title":"Br J Cancer"},{"key":"15928_CR6","doi-asserted-by":"publisher","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","volume":"7","author":"A Romanel","year":"2015","unstructured":"Romanel, A. et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. \n                           7, 312re10 (2015).","journal-title":"Sci Transl Med."},{"key":"15928_CR7","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. \n                           371, 1028\u20131038 (2014).","journal-title":"N Engl J Med."},{"key":"15928_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/jcb.10659","volume":"90","author":"E Ackerstaff","year":"2003","unstructured":"Ackerstaff, E., Glunde, K. & Bhujwalla, Z. M. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem. \n                           90, 525\u2013533 (2003).","journal-title":"J Cell Biochem."},{"key":"15928_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1586\/14737159.6.6.821","volume":"6","author":"K Glunde","year":"2006","unstructured":"Glunde, K., Jacobs, M. A. & Bhujwalla, Z. M. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn. \n                           6, 821\u2013829 (2006).","journal-title":"Expert Rev Mol Diagn."},{"key":"15928_CR10","doi-asserted-by":"publisher","first-page":"34978","DOI":"10.1074\/jbc.M205316200","volume":"277","author":"Y Yu","year":"2002","unstructured":"Yu, Y., Sreenivas, A., Ostrander, D. B. & Carman, G. M. Phosphorylation of Saccharomyces cerevisiae choline kinase on Ser30 and Ser85 by protein kinase A regulates phosphatidylcholine synthesis by the CDP-choline pathway. J Biol Chem. \n                           277, 34978\u201334986 (2002).","journal-title":"J Biol Chem."},{"key":"15928_CR11","unstructured":"Asim, M. et al. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst. 108 pii: djv371 (2015)."},{"key":"15928_CR12","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1038\/sj.onc.1205556","volume":"21","author":"A Ramirez de Molina","year":"2002","unstructured":"Ramirez de Molina, A. et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumour strategy. Oncogene \n                           21, 4317\u20134322 (2002).","journal-title":"Oncogene"},{"key":"15928_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/bjc.2013.729","volume":"110","author":"A Granata","year":"2014","unstructured":"Granata, A. et al. Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. Br J Cancer \n                           110, 330\u2013340 (2014).","journal-title":"Br J Cancer"},{"key":"15928_CR14","first-page":"3599","volume":"61","author":"E Ackerstaff","year":"2001","unstructured":"Ackerstaff, E., Pflug, B. R., Nelson, J. B. & Bhujwalla, Z. M. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. \n                           61, 3599\u2013603 (2001).","journal-title":"Cancer Res."},{"key":"15928_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.semnuclmed.2007.07.003","volume":"37","author":"SA Kwee","year":"2007","unstructured":"Kwee, S. A., DeGrado, T. R., Talbot, J. N., Gutman, F. & Coel, M. N. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med. \n                           37, 420\u2013428 (2007).","journal-title":"Semin Nucl Med."},{"key":"15928_CR16","first-page":"1064","volume":"31","author":"M Tian","year":"2004","unstructured":"Tian, M., Zhang, H., Oriuchi, N., Higuchi, T. & Endo, K. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumours. Eur J Nucl Med Mol Imaging \n                           31, 1064\u20131072 (2004).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"15928_CR17","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.3892\/mmr.2015.3200","volume":"11","author":"Z Huang","year":"2015","unstructured":"Huang, Z., Rui, J., Li, X., Meng, X. & Liu, Q. Use of \u00b9\u00b9C-Choline positron emission tomography\/computed tomography to investigate the mechanism of choline metabolism in lung cancer. Mol Med Rep. \n                           11, 3285\u20133290 (2015).","journal-title":"Mol Med Rep."},{"key":"15928_CR18","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/RLU.0000000000000604","volume":"40","author":"F Ceci","year":"2015","unstructured":"Ceci, F. et al. 11C-choline PET\/CT and bladder cancer: lymph node metastasis assessment with pathological specimens as reference standard. Clin Nucl Med. \n                           40, e124\u2013128 (2015).","journal-title":"Clin Nucl Med."},{"key":"15928_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0022-5347(05)64906-3","volume":"168","author":"DT Price","year":"2002","unstructured":"Price, D. T. et al. Comparison of [18 F] fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. \n                           168, 273\u2013280 (2002).","journal-title":"J Urol."},{"key":"15928_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2013.04.019","volume":"64","author":"MH Umbehr","year":"2013","unstructured":"Umbehr, M. H., M\u00fcntener, M., Hany, T., Sulser, T. & Bachmann, L. M. The role of 11C-choline and 18F-fluoro-choline positron emission tomography (PET) and PET\/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. \n                           64, 106\u2013117 (2013).","journal-title":"Eur Urol."},{"key":"15928_CR21","doi-asserted-by":"publisher","first-page":"12448","DOI":"10.18632\/oncotarget.2558","volume":"5","author":"U De Giorgi","year":"2014","unstructured":"De Giorgi, U. et al. Early outcome prediction on 18F-fluorocholine PET\/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget \n                           5, 12448\u201312458 (2014).","journal-title":"Oncotarget"},{"key":"15928_CR22","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00259-015-3069-7","volume":"42","author":"U De Giorgi","year":"2015","unstructured":"De Giorgi, U. et al. Erratum to: (18)F-Fluorocholine PET\/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging \n                           42, 1337\u20131338 (2015).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"15928_CR23","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. \n                           364, 1995\u20132005 (2011).","journal-title":"N Engl J Med."},{"key":"15928_CR24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. \n                           367, 1187\u20131197 (2012).","journal-title":"N Engl J Med."},{"issue":"6","key":"15928_CR25","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2967\/jnumed.113.135194","volume":"55","author":"SA Kwee","year":"2014","unstructured":"Kwee, S. A., Lim, J., Watanabe, A., Kromer-Baker, K. & Coel, M. N. Prognosis Related to Metastatic Burden Measured by 18F-Fluorocholine PET\/CT in Castration-Resistant Prostate Cancer. J Nucl Med \n                           55(6), 905\u201310 (2014).","journal-title":"J Nucl Med"},{"key":"15928_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00259-012-2280-z","volume":"40","author":"C Van de Wiele","year":"2013","unstructured":"Van de Wiele, C., Kruse, V., Smeets, P., Sathekge, M. & Maes, A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging \n                           40, 290\u2013301 (2013).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"15928_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30759","author":"P Ulz","year":"2017","unstructured":"Ulz, P., Heitzer, E., Geigl, J. B. & Speicher, M. R. Patient monitoring through liquid biopsies using circulating tumour DNA. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.30759 (2017).","journal-title":"Int J Cancer"},{"key":"15928_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1752-8062.2011.00375.x","volume":"5","author":"S Kwee","year":"2012","unstructured":"Kwee, S., Song, M. A., Cheng, I., Loo, L. & Tiirikainen, M. Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET\/CT imaging in chemotherapy-treated advanced prostate cancer. Clin Transl Sci. \n                           5, 65\u201370 (2012).","journal-title":"Clin Transl Sci."},{"key":"15928_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2967\/jnumed.114.141887","volume":"56","author":"M Cimitan","year":"2015","unstructured":"Cimitan, M. et al. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET\/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients. J Nucl Med. \n                           56, 209\u2013215 (2015).","journal-title":"J Nucl Med."},{"key":"15928_CR30","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2967\/jnumed.112.110148","volume":"4","author":"M Beheshti","year":"2013","unstructured":"Beheshti, M. et al. Impact of 18F-choline PET\/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. \n                           4, 833\u2013840 (2013).","journal-title":"J Nucl Med."},{"key":"15928_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/RLU.0b013e31823363b0","volume":"37","author":"G Giovacchini","year":"2012","unstructured":"Giovacchini, G. et al. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET\/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med. \n                           37, 325\u2013331 (2012).","journal-title":"Clin Nucl Med."},{"key":"15928_CR32","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1007\/s00259-010-1403-7","volume":"37","author":"G Giovacchini","year":"2010","unstructured":"Giovacchini, G. et al. PSA doubling time for prediction of [(11)C]choline PET\/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging \n                           37, 1106\u20131116 (2010).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"15928_CR33","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.nucmedbio.2006.08.002","volume":"33","author":"T Hara","year":"2006","unstructured":"Hara, T., Bansal, A. & DeGrado, T. R. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol. \n                           33, 977\u2013984 (2006).","journal-title":"Nucl Med Biol."},{"key":"15928_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.critrevonc.2014.05.008","volume":"92","author":"V Conteduca","year":"2014","unstructured":"Conteduca, V., Aieta, M., Amadori, D. & De Giorgi, U. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. Crit Rev Oncol Hematol. \n                           92, 11\u201324 (2014).","journal-title":"Crit Rev Oncol Hematol."},{"key":"15928_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clgc.2014.06.010","volume":"13","author":"SL Burgio","year":"2015","unstructured":"Burgio, S. L. et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer \n                           13, 39\u201343 (2015).","journal-title":"Clin Genitourin Cancer"},{"key":"15928_CR36","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/pros.23357","volume":"77","author":"V Conteduca","year":"2017","unstructured":"Conteduca, V. et al. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. Prostate \n                           77, 1012\u20131019 (2017).","journal-title":"Prostate"},{"key":"15928_CR37","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s00259-014-2982-5","volume":"42","author":"M Picchio","year":"2015","unstructured":"Picchio, M. et al. Imaging biomarkers in prostate cancer: role of PET\/CT and MRI. Eur J Nucl Med Mol Imaging \n                           42, 644\u2013655 (2015).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"15928_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/pros.22921","volume":"75","author":"JB Pinaquy","year":"2015","unstructured":"Pinaquy, J. B. et al. Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. Prostate \n                           75, 323\u2013331 (2015).","journal-title":"Prostate"},{"key":"15928_CR39","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.2217\/14622416.7.7.1109","volume":"7","author":"K Glunde","year":"2006","unstructured":"Glunde, K. & Serkova, N. J. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics \n                           7, 1109\u20131123 (2006).","journal-title":"Pharmacogenomics"},{"key":"15928_CR40","first-page":"366","volume":"45","author":"SM Larson","year":"2004","unstructured":"Larson, S. M. et al. Tumour localization of 16beta-18F-fluoro-5alphadihydrotestosterone versus 18F-FDG in patients with progressive metastatic prostate cancer. J Nucl Med \n                           45, 366\u2013373 (2004).","journal-title":"J Nucl Med"},{"key":"15928_CR41","doi-asserted-by":"publisher","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","volume":"17","author":"Y Chen","year":"2011","unstructured":"Chen, Y. et al. 2-(3-{1-carboxy-5-[(6-[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioicacid[18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. \n                           17, 7645\u20137653 (2011).","journal-title":"Clin Cancer Res."},{"key":"15928_CR42","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/RLU.0000000000001197","volume":"41","author":"C Bluemel","year":"2016","unstructured":"Bluemel, C. et al. 68Ga-PSMA-PET\/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET\/CT. Clin Nucl Med. \n                           41, 515\u2013521 (2016).","journal-title":"Clin Nucl Med."},{"key":"15928_CR43","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. \n                           26, 1148\u20131159 (2008).","journal-title":"J Clin Oncol."},{"key":"15928_CR44","first-page":"1734","volume":"45","author":"O Mawlawi","year":"2004","unstructured":"Mawlawi, O. et al. Performance characteristics of a newly developed PET\/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med. \n                           45, 1734\u20131742 (2004).","journal-title":"J Nucl Med."},{"key":"15928_CR45","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/bjc.2013.705","volume":"110","author":"AD Nygaard","year":"2014","unstructured":"Nygaard, A. D., Holdgaard, P. C., Spindler, K. L., Pallisgaard, N. & Jakobsen, A. The correlation between cell-free DNA and tumour burden was estimated by PET\/CT in patients with advanced NSCLC. Br J Cancer \n                           110, 363\u2013368 (2014).","journal-title":"Br J Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15928-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T08:36:40Z","timestamp":1671784600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15928-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["15928"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-15928-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]},"assertion":[{"value":"19 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.C. and U.D. received speaker honorarium or travel support from Astellas, Janssen-Cilag and Sanofi-Aventis. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15541"}}